Eli Lilly and Company

Other

Elanco US Inc.

Michael Robert Wiley

Gerald Floyd Smith

John Joseph Masters

Valentine Joseph Klimkowski

Ying Kwong Yee

David Kent Herron

David Mendel

Robert T Shuman

Jeffry Bernard Franciskovich

Anne Louise Tebbe

Jason Scott Sawyer

Douglas Wade Beight

James Howard Wikel

Jennifer Marie Tinsley

Steven E Hall

Leonard Crayton Weir

Trelia Joyce Craft

Theodore Goodson, Jr

Jeffrey Alan Kyle

Guy Milot

Aaron L Schacht

Sajan Joseph

Daniel Jon Sall

Stephen Clinton Young

Christopher William Murray

Stuart Donald Jones

Scott Martin Sheehan

Brian Morgan Watson

John Walter Liebeschuetz

Nicholas Paul Camp

William Alexander Wylie

Angela Lynn Marquart

David Birenbaum Engel

Ho-Shen Lin

Minsheng Zhang

Richard Waltz Harper

Kumiko Takeuchi

Jefferson Ray McCowan

Marta Maria Pi&ntilde;eiro-N&uacute;&ntilde;ez

Matthew Joseph Fisher

Jolie Anne Bastian

Andrew Michael Ratz

Nickolay Y Chirgadze

Peter Guzzo

Larry C Blaszczak

Leander Merritt

Qing Shi

Michael Alan Robertson

Philip Parker Waid

Shon Roland Pulley

Michael John Mayer

Carl Penman Denny

Marta Maria Pi&ntilde;eiro-Nu&ntilde;ez

Theodore Goodson, Junior

Alan David Palkowitz

Michael Enrico Richett

Leland O Weigel

Robert J Foglesong

Shawn Christopher Miller

Ana Maria Escribano

Brian Michael Mathes

Michael Lyle Denney

Mary George Johnson

Jeffrey Thomas Mullaney

Michael P Lynch

Todd Jonathan Kohn

Timothy Barrett Durham

Phillip John Morgan

Lian Zhu Liu

Gary Lowell Engel

Andrew David Rimmer

Xiaoqing Wang

Marta Maria Pineiro-Nunez

Simon James Richards

Celia Lafuente Blanco

Jared Harris Linebarger

Salvatore Donato Lepore

Maria Dolores Martin-Ortega Finger

Kenneth Dean Kurz

Marta Maria Pinelro-Núnez

Amanda Jane Lyons

Guy Milet

Theodore Goodson Jr

Jeffrey Bernard Franciskovich

Jolie Ann Bastian

Ankush Baburao Argade

Jothirajah Marimuthu

Robert B Rothenberger

Maria Rosario Gonzalez

Steven Douglas Hiscock

Larry Chris Blaszczak

The present invention provides a compound of Formula (I) wherein X is selected from the group consisting of (CH)&#x2014; and CH&#x2014;CH(CH)&#x2014;; Q is selected from the group consisting of C(CH)and Formula (a); or a pharmaceutically acceptable salt thereof; compositions, methods to treat liver disease and NASH. 

Imidazolidine compounds

The present invention provides compounds of the Formula below: [Formula should be inserted here] Where A, X, R. and R2-R3 are as described herein; methods of treating patients for hypertriglyceridemia and cardiovascular disease including dyslipidemia and atherosclerosis, and processes for preparing the compounds. 

DGAT2 inhibitors

The present invention provides compounds having the formula: wherein Ris selected from methyl, ethyl, propyl, cyclopropyl, and dimethyl, or a pharmaceutically acceptable salt thereof, along with methods and intermediates for their preparation, and uses thereof. 

Aggrecanase inhibitors

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C-Calkyl, C-Cfluoroalkyl, and &#x2014;OR12; R9 is selected from H &#x2014;NR13C(O)R14 and &#x2014;C(O)NR10R11; R12 is selected from H, C-Calkyl and C-Ccycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

Pyridine derivatives as dipeptedyl peptidase inhibitors

The present invention is directed to compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein A is (II); X is selected from CH, CF and N, R8 is selected from H, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O&#x2014;C-Calkyl, C-Chaloalkyl, hydroxy C-Calkyl, &#x2014;C(O)R9 and &#x2014;SOR9, or R7 and R8 combine to form (III), (IV); W is selected from CR1O and CR15, R1O is selected from H, halo, &#x2014;C(O)NR13R14, C-Calkyl, aryl, heteroaryl, C-Calkylaryl, C-Calkylheteroaryl, C-Calkyl-O&#x2014;C-Calkyl and hydroxy C-Calkyl; Het is a N-linked 5-membered heteroaryl ring optionally substituted with 1-3 substituents selected from methoxy, Cl, F, CH, CF, aryl, heteroaryl, C-Calkylaryl or C-Calkylheteroaryl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

1-amino linked compounds

The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (xx); X is selected from CH, CF and N, R5 is selected from H, C-Calkyl, C-Cfluoroalkyl, and &#x2014;OR12, R9 is selected from H and &#x2014;C(O)NR1OR1 1, R12 is selected from H, C-Calkyl and C-Ccycloalkyl for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes. 

Phenyl compounds and their use in the treatment of Type II diabetes

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a). 

Aromatic ether derivatives useful as thrombin inhibitors

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. 

Antithrombotic diamides

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor (I). 

Antithrombotic ethers

This application relates to a compound of formula I (or a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

Antithrombotic aromatic ethers

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor. 

Substituted heterocyclic carboxamides with antithrombotic activity

Compounds of formula (I) in which R, X, Y, Cy, L and Lp(D)have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.

Serine protease inhibitors

Compounds of formula (I) in which R, R, R, n and Xhave the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders

Compounds of formula (I) in which R, R, Rand R, have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Chemical compounds

Compounds of formula (I) in which R, Rand Xhave the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.

Growing community of inventors

Indianapolis, IN, United States of America

Michael Robert Wiley